Follow The Filings

AVIR Atea Pharmaceuticals Inc.

Health Care, filed as ATEA PHARMACEUTICALS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.1%
  • $1.1M
  • 1 reduce

In 2026 Q2 James Silverman trimmed Atea Pharmaceuticals.

Who owns this now

Largest portfolio weights among holders, up to 0.1% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman Reduce 0.10%

Who owns AVIR

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 0.10%, was 0.23% Reduce −27.2% 235,000 $1.1M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by AVIR's executives, directors and 10% owners in the last 12 months, from their Form 4s

All AVIR insider trades
  • $25K bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Polly A. Murphy Director
    Buy
    $25K 6,100 shares at $4.17 +7.1% to stake
    Traded May 18 Filed May 21
    ↗
  2. Polly A. Murphy Director
    Buy
    $25K 6,100 shares at $4.17 +7.1% to stake
    Traded May 18, 2025 Filed May 20
    ↗

Also filed in the last 12 months, not counted as buying or selling: 14 option exercises and 6 share withholdings for taxes.

Congress

No member of Congress reported trading AVIR in the last three years. 1 member listed it in 2025 annual reports.

All Congress trades

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 15 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$135.96M -$168.38M -$158.35M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $590.46M $462.36M $310.99M
Total non-current assets * $4.51M $2.31M $4.23M
Total assets $594.97M $464.67M $315.22M
Total current liabilities $32.38M $18.6M $39.78M
Total non-current liabilities * $7.4M $7.2M $0M
Total equity $555.19M $438.87M $275.43M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$85.4M -$135.5M -$132.03M
Cash from investing $40.3M $56.1M $188.79M
Cash from financing $0.257M $0.267M -$25.74M
Net change in cash -$44.84M -$79.13M $31.02M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.